Vivoryon

Vivoryon Therapeutics N.V. to Report Full 12 months 2025 Monetary Outcomes and Enterprise Updates on April 23, 2026
Company Announcement

Vivoryon Therapeutics N.V. to Report Full 12 months 2025 Monetary Outcomes and Enterprise Updates on April 23, 2026

Vivoryon Therapeutics N.V. Gives Replace on Rising Physique of Proof Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
Company Announcement

Vivoryon Therapeutics N.V. Gives Replace on Rising Physique of Proof Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology